• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

黑色素瘤的肿瘤内和肿瘤间异质性

Intratumor and Intertumor Heterogeneity in Melanoma.

作者信息

Grzywa Tomasz M, Paskal Wiktor, Włodarski Paweł K

机构信息

The Department of Histology and Embryology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Banacha 1b, 02-091 Warsaw, Poland.

The Department of Histology and Embryology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Banacha 1b, 02-091 Warsaw, Poland.

出版信息

Transl Oncol. 2017 Dec;10(6):956-975. doi: 10.1016/j.tranon.2017.09.007. Epub 2017 Oct 24.

DOI:10.1016/j.tranon.2017.09.007
PMID:29078205
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5671412/
Abstract

Melanoma is a cancer that exhibits one of the most aggressive and heterogeneous features. The incidence rate escalates. A high number of clones harboring various mutations contribute to an exceptional level of intratumor heterogeneity of melanoma. It also refers to metastases which may originate from different subclones of primary lesion. Such component of the neoplasm biology is termed intertumor and intratumor heterogeneity. These levels of tumor heterogeneity hinder accurate diagnosis and effective treatment. The increasing number of research on the topic reflects the need for understanding limitation or failure of contemporary therapies. Majority of analyses concentrate on mutations in cancer-related genes. Novel high-throughput techniques reveal even higher degree of variations within a lesion. Consolidation of theories and researches indicates new routes for treatment options such as targets for immunotherapy. The demand for personalized approach in melanoma treatment requires extensive knowledge on intratumor and intertumor heterogeneity on the level of genome, transcriptome/proteome, and epigenome. Thus, achievements in exploration of melanoma variety are described in details. Particularly, the issue of tumor heterogeneity or homogeneity given BRAF mutations is discussed.

摘要

黑色素瘤是一种具有最具侵袭性和异质性特征之一的癌症。其发病率不断上升。大量携带各种突变的克隆导致黑色素瘤肿瘤内异质性达到异常水平。它还指可能起源于原发性病变不同亚克隆的转移灶。肿瘤生物学的这一组成部分被称为肿瘤间和肿瘤内异质性。这些肿瘤异质性水平阻碍了准确的诊断和有效的治疗。对该主题的研究数量不断增加,反映出需要了解当代疗法的局限性或失败原因。大多数分析集中在癌症相关基因的突变上。新型高通量技术揭示了病变内更高程度的变异。理论和研究的整合为免疫治疗靶点等治疗选择指明了新途径。黑色素瘤治疗中个性化方法的需求需要在基因组、转录组/蛋白质组和表观基因组水平上对肿瘤内和肿瘤间异质性有广泛的了解。因此,将详细描述黑色素瘤多样性探索方面的成果。特别是,将讨论给定BRAF突变情况下肿瘤异质性或同质性的问题。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b64/5671412/5302375e0ebf/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b64/5671412/5302375e0ebf/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b64/5671412/5302375e0ebf/gr1.jpg

相似文献

1
Intratumor and Intertumor Heterogeneity in Melanoma.黑色素瘤的肿瘤内和肿瘤间异质性
Transl Oncol. 2017 Dec;10(6):956-975. doi: 10.1016/j.tranon.2017.09.007. Epub 2017 Oct 24.
2
Immunohistochemical and Molecular Features of Melanomas Exhibiting Intratumor and Intertumor Histomorphologic Heterogeneity.表现出肿瘤内和肿瘤间组织形态学异质性的黑色素瘤的免疫组织化学和分子特征
Cancers (Basel). 2019 Nov 2;11(11):1714. doi: 10.3390/cancers11111714.
3
Intratumor Heterogeneity Correlates With Reduced Immune Activity and Worse Survival in Melanoma Patients.肿瘤内异质性与黑色素瘤患者免疫活性降低及较差的生存率相关。
Front Oncol. 2020 Dec 4;10:596493. doi: 10.3389/fonc.2020.596493. eCollection 2020.
4
Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine.人类皮肤黑色素瘤中癌/睾丸抗原表达的肿瘤内异质性受甲基化调控,并可被5-氮杂-2'-脱氧胞苷功能逆转。
Cancer Res. 2004 Dec 15;64(24):9167-71. doi: 10.1158/0008-5472.CAN-04-1442.
5
Computed Tomography-Derived Radiomic Metrics Can Identify Responders to Immunotherapy in Ovarian Cancer.计算机断层扫描衍生的放射组学指标可识别卵巢癌免疫治疗的反应者。
JCO Precis Oncol. 2019 Aug 15;3. doi: 10.1200/PO.19.00038. eCollection 2019.
6
The significance of intertumor and intratumor heterogeneity in liver cancer.肝癌中肿瘤间和肿瘤内异质性的意义。
Exp Mol Med. 2018 Jan 5;50(1):e416. doi: 10.1038/emm.2017.165.
7
Mapping heterogeneity in patient-derived melanoma cultures by single-cell RNA-seq.通过单细胞RNA测序绘制患者来源的黑色素瘤培养物中的异质性
Oncotarget. 2017 Jan 3;8(1):846-862. doi: 10.18632/oncotarget.13666.
8
Intratumor heterogeneity in perfusion in human melanoma xenografts measured by contrast-enhanced magnetic resonance imaging.通过对比增强磁共振成像测量的人黑色素瘤异种移植瘤灌注中的肿瘤内异质性。
Magn Reson Imaging. 2000 Oct;18(8):997-1002. doi: 10.1016/s0730-725x(00)00188-0.
9
Microvascular permeability to macromolecules in human melanoma xenografts assessed by contrast-enhanced MRI--intertumor and intratumor heterogeneity.通过对比增强磁共振成像评估人黑色素瘤异种移植瘤中大分子的微血管通透性——肿瘤间和肿瘤内异质性
Magn Reson Imaging. 2001 Jun;19(5):723-30. doi: 10.1016/s0730-725x(01)00377-0.
10
Cell Culture System for Analysis of Genetic Heterogeneity Within Hepatocellular Carcinomas and Response to Pharmacologic Agents.用于分析肝细胞癌内遗传异质性和药物反应的细胞培养系统。
Gastroenterology. 2017 Jan;152(1):232-242.e4. doi: 10.1053/j.gastro.2016.09.008. Epub 2016 Sep 14.

引用本文的文献

1
Measured intrapatient radiomic variability as a predictor of treatment response in multi-metastatic soft tissue sarcoma patients.测量患者体内的放射组学变异性作为多转移性软组织肉瘤患者治疗反应的预测指标。
Sci Rep. 2025 Jul 30;15(1):27838. doi: 10.1038/s41598-025-12451-3.
2
Metastatic Melanoma Prognosis Prediction Using a TC Radiomic-Based Machine Learning Model: A Preliminary Study.基于TC影像组学的机器学习模型预测转移性黑色素瘤预后:一项初步研究
Cancers (Basel). 2025 Jul 10;17(14):2304. doi: 10.3390/cancers17142304.
3
In-depth patient-specific analysis of tumor heterogeneity in melanoma brain metastasis: Insights from spatial transcriptomics and multi-region bulk sequencing.

本文引用的文献

1
Update on the clinical use of kinase inhibitors in melanoma.黑色素瘤中激酶抑制剂的临床应用进展。
J Dtsch Dermatol Ges. 2017 Sep;15(9):887-893. doi: 10.1111/ddg.13321.
2
Advances in Immunotherapy for Melanoma: A Comprehensive Review.黑色素瘤免疫治疗的进展:全面综述。
Mediators Inflamm. 2017;2017:3264217. doi: 10.1155/2017/3264217. Epub 2017 Aug 1.
3
Multisite tumor sampling enhances the detection of intratumor heterogeneity at all different temporal stages of tumor evolution.多部位肿瘤取样可增强在肿瘤进展的所有不同时间阶段对肿瘤内异质性的检测。
黑色素瘤脑转移中肿瘤异质性的深度患者特异性分析:来自空间转录组学和多区域批量测序的见解
Transl Oncol. 2025 Sep;59:102468. doi: 10.1016/j.tranon.2025.102468. Epub 2025 Jul 15.
4
Pretreatment PET dissemination features as biomarkers for survival outcomes in melanoma patients treated with immune-checkpoint inhibitors.治疗前PET播散特征作为接受免疫检查点抑制剂治疗的黑色素瘤患者生存结局的生物标志物。
Sci Rep. 2025 Jul 1;15(1):21570. doi: 10.1038/s41598-025-95713-4.
5
Nutrition and Diet Patterns as Key Modulators of Metabolic Reprogramming in Melanoma Immunotherapy.营养与饮食模式作为黑色素瘤免疫治疗中代谢重编程的关键调节因素
J Clin Med. 2025 Jun 12;14(12):4193. doi: 10.3390/jcm14124193.
6
GPNMB marks a quiescent cell population in melanoma and promotes metastasis formation.GPNMB标记黑色素瘤中的静止细胞群并促进转移形成。
EMBO Rep. 2025 Jun 17. doi: 10.1038/s44319-025-00501-w.
7
Targeted synthesis of a trimethoxyphenyltetrahydropyrimidine analogue designed as a DNA intercalator: , multi-spectroscopic, thermodynamic, and approaches.靶向合成一种设计为DNA嵌入剂的三甲氧基苯基四氢嘧啶类似物:多光谱、热力学和[具体方法未给出]方法。
RSC Adv. 2025 May 8;15(19):14946-14965. doi: 10.1039/d5ra02179k. eCollection 2025 May 6.
8
Proteogenomic Profiling of Treatment-Naïve Metastatic Malignant Melanoma.未经治疗的转移性恶性黑色素瘤的蛋白质基因组分析
Cancers (Basel). 2025 Feb 27;17(5):832. doi: 10.3390/cancers17050832.
9
Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma.转移性黑色素瘤中获得性免疫治疗耐药的基因组介导因素。
Cancer Cell. 2025 Feb 10;43(2):308-316.e6. doi: 10.1016/j.ccell.2025.01.009.
10
Genetic concordance in melanoma: insights from primary tumors and their matched distant metastases.黑色素瘤中的基因一致性:来自原发性肿瘤及其匹配的远处转移灶的见解
Melanoma Res. 2025 Jun 1;35(3):162-169. doi: 10.1097/CMR.0000000000001024. Epub 2025 Feb 6.
Virchows Arch. 2018 Feb;472(2):187-194. doi: 10.1007/s00428-017-2223-y. Epub 2017 Aug 25.
4
Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.基因组和免疫异质性与黑色素瘤对治疗的不同反应相关。
NPJ Genom Med. 2017;2. doi: 10.1038/s41525-017-0013-8. Epub 2017 Apr 7.
5
Cell Dispersal Influences Tumor Heterogeneity and Introduces a Bias in NGS Data Interpretation.细胞分散会影响肿瘤异质性,并导致 NGS 数据解读产生偏差。
Sci Rep. 2017 Aug 4;7(1):7358. doi: 10.1038/s41598-017-07487-z.
6
Discrepancy in BRAF status among patients with metastatic malignant melanoma: A meta-analysis.转移性恶性黑色素瘤患者 BRAF 状态的差异:一项荟萃分析。
Eur J Cancer. 2017 Aug;81:106-115. doi: 10.1016/j.ejca.2017.05.015. Epub 2017 Jun 15.
7
PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison.黑色素瘤中程序性死亡受体配体1(PD-L1)的表达:定量免疫组织化学抗体比较
Clin Cancer Res. 2017 Aug 15;23(16):4938-4944. doi: 10.1158/1078-0432.CCR-16-1821. Epub 2017 Apr 20.
8
Towards Personalized Medicine in Melanoma: Implementation of a Clinical Next-Generation Sequencing Panel.迈向黑色素瘤个体化医学:临床下一代测序 panel 的实施。
Sci Rep. 2017 Mar 29;7(1):495. doi: 10.1038/s41598-017-00606-w.
9
Controversies in Intrapatient Melanoma BRAFV600E Mutation Status.患者体内黑色素瘤BRAFV600E突变状态的争议
Am J Dermatopathol. 2017 Apr;39(4):291-295. doi: 10.1097/DAD.0000000000000710.
10
COX-2 expression positively correlates with PD-L1 expression in human melanoma cells.在人黑色素瘤细胞中,COX - 2表达与PD - L1表达呈正相关。
J Transl Med. 2017 Feb 23;15(1):46. doi: 10.1186/s12967-017-1150-7.